The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 16, Issue 9, Pages 911-918
Publisher
Informa UK Limited
Online
2016-08-08
DOI
10.1080/14737140.2016.1222273
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
- (2016) S. Nilsson et al. ANNALS OF ONCOLOGY
- Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial
- (2016) Christopher Parker et al. EUROPEAN UROLOGY
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases
- (2015) S. J. Chittenden et al. JOURNAL OF NUCLEAR MEDICINE
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
- (2014) Dana E. Rathkopf et al. EUROPEAN UROLOGY
- Radiation Safety Considerations for the Use of 223RaCl2 DE in Men with Castration-resistant Prostate Cancer
- (2014) Lawrence T. Dauer et al. HEALTH PHYSICS
- Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
- (2014) Peter Hoskin et al. LANCET ONCOLOGY
- Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
- (2014) Oliver Sartor et al. LANCET ONCOLOGY
- Effect of docetaxel on safety and efficacy of radium-223
- (2014) Robert B Den et al. LANCET ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted radio-nuclide therapy of skeletal metastases
- (2012) Oliver Sartor et al. CANCER TREATMENT REVIEWS
- A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer
- (2012) Christopher C. Parker et al. EUROPEAN UROLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006
- (2011) N Sathiakumar et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Implications of Bone Metastases and the Benefits of Bone-Targeted Therapy
- (2010) Allan Lipton SEMINARS IN ONCOLOGY
- Combining Systemic Bisphosphonates with Palliative External Beam Radiotherapy or Bone-Targeted Radionuclide Therapy: Interactions and Effectiveness
- (2009) V. Vassiliou et al. CLINICAL ONCOLOGY
- Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates
- (2009) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started